Valuation: Alumis Inc.

Market Cap 3.33B 2.89B 2.7B 2.48B 4.68B 317B 4.76B 31.86B 12.48B 158B 12.51B 12.23B 522B P/E 2026 *
-9.13x
P/E 2027 * -9.55x
Enterprise Value 2.8B 2.43B 2.27B 2.08B 3.93B 266B 3.99B 26.75B 10.48B 133B 10.5B 10.27B 438B EV / Sales 2026 *
404x
EV / Sales 2027 * 124x
Free-Float
96.22%
Yield 2026 *
-
Yield 2027 * -
1 day+0.44%
1 week-1.87%
Current month-6.11%
1 month-2.73%
3 months+5.05%
6 months+0.66%
Current year+171.77%
1 week 25.29
Extreme 25.29
29.2
1 month 25.29
Extreme 25.29
31.35
Current year 7.85
Extreme 7.85
31.35
1 year 3.76
Extreme 3.76
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 23/09/2021
Director of Finance/CFO 60 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 63 01/05/2021
Director/Board Member 60 01/06/2021
Chairman 61 23/09/2021
Date Insider Type Main position Quantity % Market Cap.
7/6/26 A Fiscal year

General Counsel

15,000 0.0122%
6/30/26 A Free

Director

19,081 0.0155%
6/30/26 A Free

Director

19,081 0.0155%
Change 5-day change 1-year change 3-year change Capi.($)
+0.44%-1.87%+548.53% - 3.33B
+0.05%+3.08%+38.17%+66.77% 56.7B
+0.30%-6.17%+23.28%+61.84% 51.97B
-0.93%-0.40%-16.31%-13.52% 23.33B
-0.52%-5.28%-11.34%+348.52% 21.34B
+1.67%-0.97%+33.63%-25.35% 17.44B
+9.91%-2.51%+188.84%+326.19% 14.77B
+0.92%-1.27%+51.56%+175.23% 13.84B
+0.56%+1.95%+431.13%+176.30% 12.12B
+2.35%-7.30%+60.03%+156.82% 11.14B
Average +1.56%-2.45%+134.75%+141.42% 22.6B
Weighted average by Cap. +0.99%-1.97%+64.43%+111.42%

Financials

2026 *2027 *
Net sales 6.93M 6.02M 5.62M 5.16M 9.73M 660M 9.9M 66.28M 25.96M 329M 26.02M 25.44M 1.09B 23.83M 20.71M 19.34M 17.75M 33.48M 2.27B 34.06M 228M 89.31M 1.13B 89.53M 87.55M 3.74B
Net income -375M -326M -304M -279M -526M -35.73B -536M -3.59B -1.4B -17.82B -1.41B -1.38B -58.77B -397M -345M -322M -296M -557M -37.82B -567M -3.8B -1.49B -18.86B -1.49B -1.46B -62.21B
Net Debt -534M -464M -434M -398M -751M -50.94B -764M -5.11B -2B -25.4B -2.01B -1.96B -83.79B -371M -322M -301M -276M -521M -35.34B -530M -3.55B -1.39B -17.62B -1.39B -1.36B -58.13B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
226
Date Price Change Volume
04/08/26 $26.51 +1.49% 67,854
03/08/26 $26.12 -7.54% 1,387,984
31/07/26 $28.25 -2.42% 1,321,121
30/07/26 $28.95 +9.74% 992,199
29/07/26 $26.38 -2.40% 820,832
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
26.12USD
Average target price
40.11USD
Spread / Average Target
+53.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock